Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastrointestinal Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GUCY2C drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GUCY2C ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed. |
View GUCY2C Products |
| Gene Delivery | GUCY2C Promise-ORF / Lentivirus Particles Full-length ORF for stable cell lines and cGMP reporter construction. Essential for membrane conformation preservation. |
View GUCY2C Products |
| Functional Pair | GUCA2A (Guanylin) Recombinant Protein Endogenous ligand for competitive binding and activation studies. |
View GUCA2A Products |
| Benchmark Ab | Anti-GUCY2C Monoclonal Antibody Recombinant positive control for binding, internalization, and assay calibration. |
View GUCY2C Products |
| Validator | GUCY2C siRNA Set For target specificity verification, knockdown assays, and rigorous specificity checks. |
View GUCY2C Products |
| Pathway Partner | CFTR Downstream ion channel regulated by GUCY2C-cGMP axis. |
View CFTR Products |
| Related Target A | CEACAM5 Synergistic target in colorectal and gastrointestinal cancers. |
View CEACAM5 Products |
| Related Target B | CLDN18.2 Key combination or alternative target for gastric cancer pipelines. |
View CLDN18.2 Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Glycosylation | HEK293 Expressed ECD-Fc ensures native human glycosylation patterns. |
| Membrane Conformation for CAR-T/Bispecifics | Lentivirus Premade Particles for rapid stable cell line construction. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included for precise assay calibration. |
| Specificity & False Positives | Validated siRNA included for rigorous specificity checks and target knockdown. |
| Internalization Efficiency (ADC development) | High-purity ECD-Fc (>95%) with native conformation for antibody internalization kinetics. |
| Functional cGMP Signaling | Lentivirus-delivered full-length GUCY2C in HEK293 cells preserves signaling cascade for functional screens. |
| Cross-species Translation (Mouse/Cyno) | Human/Mouse/Cynomolgus ortholog proteins available with sequence verification. |
| Ligand Competition Assays | Matched GUCA2A/GUCA2B ligand proteins for competitive binding studies. |
| Off-target Selectivity | Purified GUCY2C vs. GUCY2D (retinal) ortholog panel for specificity screening. |
Live GUCY2C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GUCY2C therapeutics is intensifying, with a strategic pivot from early vaccine-based and traditional monoclonal antibody approaches toward Antibody-Drug Conjugates (ADCs) and CAR-T cell therapies. As a highly specific marker for gastrointestinal malignancies (colorectal, gastric, pancreatic), GUCY2C offers an ideal therapeutic window due to its restricted expression in intestinal epithelium and uniform overexpression in tumors. Foundational work by academic institutions (Baylor College of Medicine, Johns Hopkins) and early pharmaceutical development (Takeda/Millennium) has validated its druggability. The next wave of R&D is targeting optimized internalization kinetics for ADCs, dual-targeting bispecifics to overcome tumor heterogeneity, and CAR-T cell therapies for solid tumors. Combination strategies with immune checkpoint inhibitors are also emerging for microsatellite-stable (MSS) CRC subsets. Functional agonists (e.g., linaclotide analogs) continue to be developed for constipation disorders, leveraging the receptor's physiological role in cGMP signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Takeda, Millennium, Emerging Biotechs | Colorectal, Gastric Cancers, mCRC | Internalization Assay (Need high-purity HEK293 ECD-Fc with native glycosylation) |
| CAR-T | Legend Biotech, CARsgen, Preclinical Academic Labs | GI Solid Tumors, Metastatic CRC | FACS Binding (Need Lentivirus stable cell lines for cell surface expression validation) |
| Bispecific T-cell Engagers | Pfizer, Amgen | Metastatic Colorectal Cancer | Heterodimer Validation (Need sequence-verified antigens for binding characterization) |
| Cancer Vaccine | Academic Institutions (Baylor, etc.) | Adjuvant CRC | Immunogenicity Screening (Need ECD protein for immune response mapping) |
| Functional Agonist | Pharma (Linaclotide analogs) | Constipation Disorders | cGMP Accumulation Assay (Need full-length receptor expression for functional studies) |
Molecular and Genetic Insights
GUCY2C (Guanylate Cyclase 2C) contains two key functional domains: a Protein kinase domain and a Guanylate cyclase domain (UniProt P25092). Key mutations include rs56142849 (dbSNP), a somatic mutation found in metastatic melanoma sample (VAR_042222), and rs56275235 (dbSNP). These genetic variations can influence drug response and patient stratification.